🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Walvax Biotechnology Co., Ltd. (SHE:300142)
China flag China · Delayed Price · Currency is CNY
10.00
-0.64 (-6.02%)
Nov 20, 2026, 3:04 PM CST

Walvax Biotechnology Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,8412,4132,8044,1065,0793,452
Other Revenue
5.725.7217.867.927.6510.5
1,8462,4182,8214,1145,0863,463
Revenue Growth
-23.03%-14.29%-31.41%-19.12%46.89%17.82%
Cost of Revenue
527.26631.8742.2749.39673.14403.54
Gross Profit
1,3191,7862,0793,3644,4133,059
Selling, General & Admin
989.561,2451,3991,8172,3021,636
Research & Development
232.66291.81595.77776.43922.25616.36
Other Operating Expenses
4.23-3.46-4.12-10016.4819.83
Operating Expenses
1,2231,6822,0552,5333,2392,267
Operating Income
96.35104.3324.01831.051,174792.22
Interest Expense
-28.07-0.91-8.43-5.95-7.11-5.77
Interest & Investment Income
27.6169.7866.7581.3581.82103.29
Currency Exchange Gain (Loss)
-2.63-2.634.053.060.82-0.22
Other Non Operating Income (Expenses)
-13.932.34169.74-63.64-75.3933.88
EBT Excluding Unusual Items
79.33172.91256.12845.861,174923.4
Gain (Loss) on Sale of Investments
-123.0829.68-98.34-234.75-199.33-280.74
Gain (Loss) on Sale of Assets
0.260.08-1.77-0.83-0.380.23
Asset Writedown
18.78-88.25-7.68-11.31-1.66-5.11
Other Unusual Items
78.2851.6936.17-97.871.15
Pretax Income
53.57166.11184.5598.981,070708.95
Income Tax Expense
35.1540.9610.187.65132.24107.59
Earnings From Continuing Operations
18.41125.16174.4511.33938.23601.35
Net Income to Company
18.41125.16174.4511.33938.23601.35
Minority Interest in Earnings
3.4252.58-32.24-91.93-209.57-173.6
Net Income
21.84177.74142.16419.39728.65427.75
Net Income to Common
21.84177.74142.16419.39728.65427.75
Net Income Growth
-55.66%25.03%-66.10%-42.44%70.35%-57.36%
Shares Outstanding (Basic)
1,6031,6001,5991,6001,6031,569
Shares Outstanding (Diluted)
1,6031,6001,5991,6001,6041,573
Shares Change
0.25%0.05%-0.06%-0.21%1.93%0.90%
EPS (Basic)
0.010.110.090.260.450.27
EPS (Diluted)
0.010.110.090.260.450.27
EPS Growth
-55.77%24.97%-66.08%-42.32%67.12%-57.74%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
388.18-18.62486.49188.25110.31-398.21
Free Cash Flow Per Share
0.24-0.010.300.120.07-0.25
Dividend Per Share
0.1250.1550.0100.0100.0100.027
Dividend Growth
212.50%1450.00%0%0%-62.96%-61.43%
Gross Margin
71.44%73.87%73.69%81.78%86.77%88.35%
Operating Margin
5.22%4.31%0.85%20.20%23.08%22.88%
Profit Margin
1.18%7.35%5.04%10.20%14.32%12.35%
Free Cash Flow Margin
21.02%-0.77%17.24%4.58%2.17%-11.50%
EBITDA
490.89485.6387.611,1211,422927.65
EBITDA Margin
26.59%20.08%13.74%27.25%27.96%26.79%
D&A For EBITDA
394.54381.28363.59289.97248.4135.43
EBIT
96.35104.3324.01831.051,174792.22
EBIT Margin
5.22%4.31%0.85%20.20%23.08%22.88%
Effective Tax Rate
65.63%24.65%5.48%14.63%12.35%15.18%
Revenue as Reported
1,8462,4182,8214,1145,086-
Advertising Expenses
-28.2842.6678.0194.8324.15